OneMedPlace Welcomes ImmunoVaccine Technologies, Inc. (IVT), as a Presenting Company at Their Annual OneMedForum2009 in San Francisco, January 13, 2009

New York, NY, January 11, 2009 --(PR.com)-- ImmunoVaccine Technologies, Inc. (IVT), a privately held clinical-stage company, announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA from January 13-14, 2009. Randal Chase, CEO of ImmunoVaccine Technologies, will present on Tuesday, January 13th at 8:45 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. Information about the OneMedPlace Finance forum may be found at www.onemedplace.com.

IVT is focused on developing an early stage human health vaccine pipeline consisting of infectious disease and therapeutic cancer products. Therapeutic cancer vaccines, along with the development of new infectious diseases, are expected to drive the growth of the vaccine industry.

About ImmunoVaccine Technologies:
IVT is developing breakthrough vaccine vehicles that provide long-lasting immunity with a single administration without significant side effects.. For additional information on ImmunoVaccine Technologies, please visit our website at www.immunovaccine.com or contact the Company at (902) 492-1819.

About OneMedPlace: OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine—emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.

###